BioMS Medical has announced that results of a Phase II and long-term follow-up treatment of multiple sclerosis (MS) patients with MBP8298 have been published in the European Journal of Neurology (EJN). The publication highlights long-term efficacy, safety and mechanism of action data in respect of MBP8298.
The results show that MBP8298 safely delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75 percent of MS patients, had a median time to disease progression of 78 months as compared to 18 months for patients who received placebo.